Nomura Asset Management Co. Ltd. Has $9.19 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Nomura Asset Management Co. Ltd. trimmed its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 10.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,637 shares of the biotechnology company's stock after selling 2,908 shares during the quarter. Nomura Asset Management Co. Ltd. owned about 0.06% of United Therapeutics worth $9,187,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in UTHR. ClariVest Asset Management LLC boosted its stake in United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock valued at $25,000 after buying an additional 42 shares in the last quarter. USA Financial Formulas acquired a new stake in United Therapeutics in the 3rd quarter valued at about $33,000. Brooklyn Investment Group bought a new position in shares of United Therapeutics during the 3rd quarter valued at about $33,000. V Square Quantitative Management LLC acquired a new position in shares of United Therapeutics in the 2nd quarter worth approximately $30,000. Finally, Innealta Capital LLC bought a new stake in shares of United Therapeutics in the 2nd quarter worth approximately $33,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Price Performance

United Therapeutics stock traded down $0.55 during trading hours on Thursday, hitting $361.61. The company had a trading volume of 244,694 shares, compared to its average volume of 448,382. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82. The firm has a market capitalization of $16.14 billion, a P/E ratio of 16.01, a price-to-earnings-growth ratio of 1.07 and a beta of 0.54. The firm's fifty day moving average is $369.59 and its 200-day moving average is $340.92.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the prior year, the business posted $5.38 earnings per share. Analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on UTHR shares. Oppenheimer raised their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. TD Cowen raised their price objective on United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a research note on Monday, October 21st. Argus boosted their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH upped their target price on United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a report on Thursday, October 31st. Finally, StockNews.com raised United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $370.86.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 15,000 shares of the business's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company's stock, valued at $1,034,510.88. The trade was a 85.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the transaction, the executive vice president now owns 36,710 shares in the company, valued at approximately $13,485,785.60. This trade represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 119,340 shares of company stock valued at $44,765,530 in the last three months. Corporate insiders own 11.90% of the company's stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.